Managing Incidental Genomic Findings in Clinical Trials: Fulfillment of the Principle of Justice by Dal-Ré, R et al.
Policy Forum
Managing Incidental Genomic Findings in Clinical Trials:
Fulfillment of the Principle of Justice
Rafael Dal-Re´1*, Nicholas Katsanis2, Sara Katsanis3, Lisa S. Parker4, Carmen Ayuso5,6
1Clinical Research Program, Pasqual Maragall Foundation, Barcelona, Spain, 2Center for Human Disease Modeling, Department of Cell Biology, Department of Medicine,
Duke University, Durham, North Carolina, United States of America, 3Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, United
States of America, 4Center for Bioethics and Health Law, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 5Department of Genetics, Health
Research Institute–Jimenez Diaz Foundation University Hospital (IIS-FJD), Madrid, Spain, 6CIBERER (Centro de Investigacio´n Biome´dica en Red de Enfermedades Raras),
Instituto de Salud Carlos III, Madrid, Spain
Three basic principles are key in
assessing the ethics of any research con-
ducted on humans: respect for persons (or
autonomy), beneficence, and justice [1].
Respect for persons entails individuals
being afforded the right to decide what
should happen to them; this principle is
fulfilled through a valid informed consent
process. Research participants should ex-
pect investigators to make all efforts to
secure their well-being, i.e., far beyond the
‘‘do not harm’’ Hippocratic maxim: be-
neficence refers to ensuring a favorable
benefit/risk assessment of the proposed
research. The principle of justice requires
that research’s benefits and burdens be
distributed fairly, and that research avoids
the injustice resulting ‘‘when some benefit
to which a person is entitled is denied
without good reason’’ [1]. Initially under-
stood as a principle to protect vulnerable
people from the risks of clinical research,
since the 1980s, when HIV/AIDS patients
drew attention to the potential medical
benefit of enrolling in clinical trials, this
principle is understood also to encompass
fair access to the potential benefits of
research participation [2]. Thus, in addi-
tion to altruistic reasons, some participants
enroll in clinical trials with the hope, or
even expectation, that participation offers
an opportunity to benefit through treat-
ment, medical care, and disease monitor-
ing to which, in some circumstances, the
participants may otherwise lack access.
Increasingly, clinical trials to develop
new drugs and biologics involve whole
genome or exome sequencing (WGS/
WES), including for biomarker character-
ization, for identification of genomic risk
factors, and for population-based research
[3]. WGS/WES by nature produces
incidental genomic findings, i.e., findings
that have potential health or reproductive
importance discovered in the course of
conducting research but beyond the aims
of the study [4]. In determining how to
manage incidental genomic findings in
clinical trials, we suggest two themes for
consideration: (1) the maintenance of
clinical standards of care for WGS/WES
and (2) the obligation of investigators to
manage trial participants fairly.
In response to growing recognition that
actionable incidental genomic findings
could be of value for patient care, the
American College of Medical Genetics
and Genomics (ACMG) published recom-
mendations for management of incidental
genomic findings obtained in clinical
practice [5]. The ACMG recommends
that clinical genome sequencing laborato-
ries actively seek and report pathogenic
variants identified in 56 genes associated
with 24 conditions, all with evidence that
early intervention can prevent or amelio-
rate severe adverse medical outcomes
[5,6] (Box 1). The appropriate approach
to handling incidental genomic findings in
the clinical context is under substantial
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Summary Points
N Genome/exome data are likely to play an increasing role in clinical trials, and
incidental findings are likely to be viewed as potential benefits for individuals of
research participation.
N Participants in clinical trials across differing trial sites utilizing genome/exome
sequencing information should be afforded the same standard of care,
including return of incidental genomic findings.
N Participants may opt in to receiving incidental genomic findings, and clinical
trial investigators should implement mechanisms to ensure provision of timely
and appropriate care to prevent or ameliorate conditions associated with
incidental findings.
N Ensuring the provision of such interventions in countries lacking a universal
public health-care system may prove more challenging than in countries with
public health-care support.
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debate [7–12]. Relevant sets of recom-
mendations are to be issued in due course
[13,14]. Nevertheless, it is reasonable to
assume that a standard of care will emerge
for returning incidental genomic findings
to patients receiving WGS/WES in clin-
ical contexts. In anticipation of this
eventuality, it will be important for
stakeholders to consider the relevance of
such a standard of care for ethical clinical
trial design and conduct.
Returning Incidental Genomic
Findings in Clinical Trials
Employing WGS/WES in clinical trials
could advance the development of new
treatments and diagnostic tools for many
disorders and conditions, for instance, in
oncology [15]. However, ethical and
regulatory issues regarding the manage-
ment of incidental genomic findings
should be addressed before WGS/WES
is performed routinely in therapeutic trials.
If we assume that the deliberate search for
genetic variants will become the standard
of care in the clinical setting, it is
reasonable to expect the same standards
to be applied to participants in clinical
trials.
In recent years, the idea that investiga-
tors have ‘‘ancillary care’’ obligations to
their study participants has emerged [16].
Ancillary care exceeds the demands of the
particular study interventions, sound sci-
entific practice, participant safety, and
response to adverse events. Although
ancillary care is sometimes considered to
be owed as a matter of justice or
beneficence, the obligation to provide such
care is grounded ethically in the investi-
gator–participant relationship and the
special permissions granted to investiga-
tors by participants during informed
consent [17]. Following the ancillary care
framework [16,18], it seems appropriate to
apply a standard-of-care list of genes for
which to actively seek pathogenic variants
in clinical research. If, as standard of care,
a patient could be informed of particular
variants reported as actionable incidental
genomic findings when visiting a physi-
cian, it is reasonable to argue that the
same patient, as a participant in a trial
involving WGS/WES, may have the right
to be informed about those same inciden-
tal genomic findings.
Although the potential benefit associat-
ed with identification of an incidental
genomic finding resides largely in its
informational value, for individuals to
receive the full benefit of learning of an
incidental genomic finding, subsequent
preventive interventions would need to
be undertaken to prevent or ameliorate
the manifestation of the associated condi-
tion. Ensuring that this benefit is distrib-
uted fairly to all participants in a clinical
trial involving WGS/WES presents par-
ticular challenges.
Management of Trial
Participants’ Care following
Disclosure of Incidental
Genomic Findings
Because justice demands that similar
people be treated similarly and that
irrelevant differences between them should
not result in differential benefit [1], justice
in clinical trials requires that participants
have equitable access to potential benefits
of research, including the benefits that
may result from learning of an incidental
genomic finding. Since learning of inci-
dental genomic findings identified by
WGS/WES is a potential benefit of study
participation—as indeed it is, if access to
such information is considered standard of
care in the clinical care context—then this
opportunity should be afforded to all study
participants, regardless of differences, such
as their personal ability to afford medical
care for the condition associated with the
incidental genomic finding or their access
to public universal health care.
If the standard of care for clinical
WGS/WES evolves to include actively
seeking a list of genetic variants associated
with actionable medical conditions, then
participants in clinical trials involving
WGS/WES may justifiably expect to
receive sequencing information to pro-
mote their health [19]. Given that re-
search protocols require the ethically
appropriate conduct of clinical trials across
all sites and countries, all participants in a
given trial, irrespective of the different
health-care systems of the localities in-
volved, should have access to the same (or
similar) patient care procedures and facil-
ities, including appropriate incidental ge-
nomic finding management.
Varying types of health-care systems at
trial sites could present a significant
challenge with regards to the health-care
delivery response to incidental genomic
findings. If an incidental genomic finding
is to be reported to a trial participant, the
investigator would be responsible for
provision of comprehensive counseling
including discussion of available interven-
tion choices. While, ideally, all treatment
and care choices resulting from participa-
tion would be provided free of charge to a
trial participant, in reality, access to
interventions will vary based on the
clinical trial site. If the country where the
trial is conducted has a universal public
health-care system, it would seem reason-
able that the public system would provide
treatment in advance of disease manifes-
tation. This is reasonable since if the trial
participant had not undergone the WGS/
WES, and hence had not received any
intervention to prevent the development of
the disease, the public health care system
eventually would have had to address
treatment of the disease when it manifest-
ed.
However, in regions lacking a universal
public health-care system, a clinical trial
sponsor could justifiably be held responsi-
ble for implementing mechanisms to
ensure the provision of the interventions
needed by all participants facing medically
actionable incidental genomic findings.
Institutional Review Boards/Research
Ethics Committees (IRB/RECs) would
be expected to approve trial protocols
with WGS/WES only if all potential
participants are assured in the informed
consent process that any incidental geno-
mic findings will be properly managed, as
per the standard of care. Although impor-
tant in any trial, this is especially relevant
in international clinical trials, where the
sponsor has an obligation to fulfill the
requirements of the principle of justice
across all countries and settings. Inade-
quate intervention in response to inciden-
tal genomic findings resulting from WGS/
WES should not be a means of discrim-
ination among trial participants within the
same or across different countries. Rele-
vant IRB/RECs should review the
mechanisms of providing the appropriate
standard of care and the nature, duration,
and limits of interventions to be provided.
Maintenance of Justice in
Multicenter Clinical Trials
Because most conditions associated with
actionable genetic variants (such as those
listed by the ACMG) will require long-
term management, sponsors could be
tempted to conduct trials involving consti-
tutional WGS/WES only in countries with
universal public health-care systems. This
would have an unethical discriminatory
effect, both depriving members of some
countries or communities of the potential
benefits of clinical trial participation and
failing to demonstrate the relevance of trial
outcomes for members of those popula-
tions. To avoid this potential injustice,
sponsors should consider securing a
health-care insurance agreement for trial
participants to assure access to the inter-
ventions needed to manage any reported
incidental genomic findings.
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All participants in clinical trials, includ-
ing international trials, have the right to be
treated with the standard of care. In
countries—including low- or middle-in-
come countries—where the standard of
care may be very different from that of
a wealthy country (or may not even exist), it
has been suggested in other circumstances
[20] that the external sponsor should reach
an agreement with the IRB/REC of its
own country and with the trial investiga-
tors, the health authorities, and the IRB/
REC of the site (host) country regarding
mechanisms to coordinate appropriate care
in order to maintain justice.
Finally, some commentators [21] have
suggested that concern for facing liability
for nondisclosure of actionable incidental
genomic findings may prompt some Unit-
ed States–based clinical investigators to
actively search for ACMG-recommended
incidental genomic findings to avoid
negligence-based malpractice [22]. In
other countries, however, investigators
may not feel legally motivated to search
for incidental genomic findings in their
trial participants. The different legal
climates of trial sites could be another
source of discrimination among partici-
pants in the same international trial that
could be prevented by asking all site
investigators to adhere to the same
standard for incidental genomic finding
searches.
Further Reflections on
Returning Incidental Genomic
Findings
The number of trial participants likely
to be affected is relevant for estimating the
likely cost of managing incidental genomic
findings as an obligation of ancillary care.
One (or more) mutations—if the ACMG
list would be applied—is presumed to be
present in 1% of all trial participants [5].
This would mean that, for instance, since
75% of all oncology trials recruit no
more than 100 patients [23], the
expected (mean) number of patients with
incidental genomic findings would be one
per trial.
The ACMG recommendation that in-
cidental genomic findings be reported
regardless of a patient’s preference regard-
ing whether to receive this information [5]
has been rejected on the grounds that
patients have a right ‘‘not to know’’
genomic information and that imposing
such findings would fail to respect patient
autonomy [7,24]. The ACMG recommen-
dations also have been challenged as
scientifically premature [25] and are
controversial with regard to incidental
genomic findings discovered in children
[25,26].
Emerging data show that some individ-
uals want to receive all types of WGS/
WES information—including those geno-
mic results that cannot be interpreted [19].
We believe that as a general rule it is
required ethically only to inform research
participants who have opted to receive
information of any actionable incidental
genomic finding that can be medically
managed [4]. Whether the international
community endorses the ACMG list or a
similar one for routine clinical practice, in
effect establishing a standard of care, we
propose that therapeutic trials should
incorporate a similar standardized ap-
proach to reporting incidental genomic
findings found in WGS/WES as part of a
trial.
We feel that in a research context,
participants’ autonomous decision not to
know genomic information should be
respected. To respect the autonomy of
clinical trial participants, explanation of
the possibility that WGS/WES will result
in incidental genomic findings should be
disclosed as part of the consent process.
Participants should receive comprehensive
pre-sequencing counseling and be in-
formed of the options to learn or not learn
of any resulting incidental genomic find-
ing. They should also have the option of
changing their minds with regard to
learning of incidental genomic findings at
Box 1. Examples of Genes and Associated Diseases/Conditions
Recommended by the American College of Medical Genetics
and Genomics for Reporting of Incidental Findings in Clinical
Exome and Genome Sequencing [5]: Age of Onset and
Prevention Strategies.
Example 1 [29]
a. Genes/diseases: BRCA1, BRCA2/breast and ovarian cancers
b. Age of onset: Breast cancer, $25 years old; ovarian cancer, $40 years old
c. Prevention interventions for women:
N Breast cancer: ,25 years old: annual clinical breast exam; .25 years old:
surveillance (annual mammography and magnetic resonance imaging);
clinical breast exam (every six months) or prophylactic bilateral mastectomy;
chemoprevention: not proven
N Ovarian cancer: 30–35 years old: periodic screening (blood test for CA-125 and
transvaginal ultrasonography); .35 years old: prophylactic bilateral salpingo-
oophorectomy
Example 2 [30]
a. Genes/diseases: PKP2, DSP, DSC2, TMEM43, DSG2/arrhythmogenic right
ventricular cardiomyopathy/dysplasia
b. Age of onset: Usually from adolescence onwards (4–64 years old)
c. Prevention interventions:
N Prevention of sudden cardiac death by dramatically reducing exercise and
discontinuing competitive athletics
N Prevention or delay of disease progression: beta-blockers and angiotensin-
converting enzyme inhibitors
N Electrocardiogram monitoring (to detect sustained ventricular tachycardia,
arrythmogenic syncope, or frequent ventricular ectopy and/or non-sustained
ventricular tachycardia)
Example 3 [31]
a. Genes/diseases: LDLR, APOB, PCSK9/familial hypercholesterolemia
b. Age of onset: homozygous: adolescence; heterozygous: men—heart attacks in
$40 s (85% had one by age 60); women—heart attacks in $50 s
c. Prevention interventions:
N Children and adolescents: diet
N Children and adults: lifestyle interventions (diet, physical activity, no smoking)
N Drugs to be considered (e.g., for elevated low-density lipoprotein or other risk
factors): statins, bile and sequestrant resins, niacin, ezetemibe, gemfibrozil,
fenofibrate, and others
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any point during the trial [7,27], prior to
actual disclosure of an identified
incidental genomic finding. Furthermore,
to ensure requisite validity of the finding,
upon identification of an incidental geno-
mic finding that is a candidate for
disclosure (i.e., one that is to be offered
according to the prevailing clinical stan-
dard of care), the incidental genomic
finding should be confirmed in accordance
with clinical laboratory standards and
regulations [28].
Conclusion
In anticipation of genome sequencing
becoming commonplace in clinical trials,
from the beginning, the scientific commu-
nity should be respectful of the rights
of all participants, regardless of where
they are recruited. Among these rights is
the right to receive the standard of care
regarding reporting of incidental genomic
findings and provision of interventions
necessary to prevent or ameliorate medical
conditions associated with those findings.
The challenges of developing a common
approach for clinical trials involving
WGS/WES warrant an open debate
among stakeholders (funding organiza-
tions, investigators, regulators, IRB/REC
members, bioethicists, and patient advo-
cates) in the clinical research enterprise.
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